Academic Highlights: New Developments in the Treatment of Alzheimer's Disease [CME]
J Clin Psychiatry 2009;70(2):281-290
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
First identified as a disease process
in the early 1900s, today Alzheimer’s
disease (AD) looms as a public health
crisis. In 2000, an estimated 4.5 million
persons in the United States had
mild, moderate, or severe AD; this figure could grow to 13.2 million by
2050. Peter V. Rabins, MD, MPH,
brought together a group of experts to
discuss ways to better diagnose and
more effectively treat this rapidly
As the population ages and survival
rates increase for patients with AD, not
only will the number of persons with
the disease increase rapidly, said Neill
Graff-Radford, MB BCh, FRCP, but
also the age distribution of persons
with AD will change.